# Decentralised Manufacture: Labelling

Source: https://www.keypedia.com/records/uk_mhra_guidance/uk-mhra/d6044b5d-96d9-4277-8c54-e23163b2d302
Type: Detailed Guide
Published: June 10, 2025

> This guidance document from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines the essential labeling standards for medicinal products, including unlicensed and investigative types, as defined under UK legislation. While all products must generally meet strict statutory labeling requirements, a specific exemption is provided for products manufactured at the Point of Care (POC). This exception applies only when the product is intended for immediate administration—defined as being used entirely within two minutes of manufacture without any portion being retained. For all other cases, manufacturers must ensure full compliance with identification standards. To prevent potential issues with traceability or safety, the MHRA advises manufacturers to pre-label final product and transfer containers with both the product name and a specific patient identifier. Although this excerpt does not list a specific company or inspection dates, it serves as a critical regulatory framework for maintaining safety during the rapid manufacturing and delivery of medicinal products. Failure to adhere to these labeling rules for any product not meeting the immediate administration criteria would constitute a breach of UK medicinal legislation. Professional compliance involves ensuring that all containers are clearly identified to protect patient safety during the administration process.

---

## Content

The labelling requirements pertinent to the type of medicinal product and its supply status (unlicensed, investigative medicinal product, medicinal product) as defined in UK legislation should be met. The sole exception are medicinal products manufactured at Point of Care ( POC ) which require to be administered immediately and for which no portion of the medicinal product will be retained for subsequent administration. Immediate administration is considered to represent administration immediately (for example within 2 minutes of completion of manufacture) and entirely after its manufacture. The manufacturer is encouraged to pre-label all applicable final product and/or transfer containers with a medicinal product and patient identifier.